|
1
|
American Cancer Society: Cancer Facts and
Figures. American Cancer Society; Atlanta, GA: pp. 30303–1002.
2009
|
|
2
|
Catalano MG, Poli R, Pugliese M, Fortunati
N and Boccuzzi G: Emerging molecular therapies of advanced thyroid
cancer. Mol Aspects Med. 31:215–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fassnacht M, Kreissl MC, Weismann D and
Allolio B: New targets and therapeutic approaches for endocrine
malignancies. Pharmacol Ther. 123:117–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel KN and Shaha AR: Poorly
differentiated and anaplastic thyroid cancer. Cancer Control.
13:119–128. 2006.PubMed/NCBI
|
|
5
|
Sakorafas GH, Sampanis D and Safioleas M:
Cervical lymph node dissection in papillary thyroid cancer: Current
trends, persisting controversies, and unclarified uncertainties.
Surg Oncol. 19:e57–e70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimaoka K, Schoenfeld DA, DeWys WD,
Creech RH and DeConti R: A randomized trial of doxorubicin versus
doxorubicin plus cisplatin in patients with advanced thyroid
carcinoma. Cancer. 56:2155–2160. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ahuja S and Ernst H: Chemotherapy of
thyroid carcinoma. J Endocrinol Invest. 10:303–310. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fleming ID, Phillips JL, Menck HR, Murphy
GP and Winchester DP: The national cancer data base report on
recent hospital cancer program progress toward complete American
joint committee on cancer/TNM staging. Cancer. 80:2305–2310. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gilliland FD, Hunt WC, Morris DM and Key
CR: Prognostic factors for thyroid carcinoma. A population-based
study of 15, 698 cases from the surveillance, epidemiology and end
results (SEER) program 1973–1991. Cancer. 79:564–573. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A National Cancer Data Base report on 53, 856 cases of
thyroid carcinoma treated in the U.S., 1985–1995 [see comments].
Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ain KB: Anaplastic thyroid carcinoma:
Behavior, biology, and therapeutic approaches. Thyroid. 8:715–726.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Are C and Shaha AR: Anaplastic thyroid
carcinoma: Biology, pathogenesis, prognostic factors, and treatment
approaches. Ann Surg Oncol. 13:453–464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jereb B, Stjernswärd J and Löwhagen T:
Anaplastic giant cell carcinoma of the thyroid. A study of
treatment and prognosis. Cancer. 35:1293–1295. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Junor EJ, Paul J and Reed NS: Anaplastic
thyroid carcinoma: 91 patients treated by surgery and radiotherapy.
Eur J Surg Oncol. 18:83–88. 1992.PubMed/NCBI
|
|
15
|
Tan RK, Finley RK III, Driscoll D,
Bakamjian V, Hicks WL Jr and Shedd DP: Anaplastic carcinoma of the
thyroid: A 24-year experience. Head Neck. 17:41–47; discussion
47–48. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tallroth E, Wallin G, Lundell G, Löwhagen
T and Einhorn J: Multimodality treatment in anaplastic giant cell
thyroid carcinoma. Cancer. 60:1428–1431. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moro CO and Basile G: Obesity and
medicinal plants. Fitoterapia. 71:(Suppl 1). S73–S82. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saha M, Rempt M, Grosser K, Pohnert G and
Weinberger F: Surface-associated fucoxanthin mediates settlement of
bacterial epiphytes on the rockweed Fucus vesiculosus.
Biofouling. 27:423–433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kwak KW, Cho KS, Hahn OJ, Lee KH, Lee BY,
Ko JJ and Chung KH: Biological effects of fucoidan isolated from
Fucus vesiculosus on thrombosis and vascular cells. Korean J
Hematol. 45:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parys S, Kehraus S, Krick A, Glombitza KW,
Carmeli S, Klimo K, Gerhäuser C and König GM: In vitro
chemopreventive potential of fucophlorethols from the brown alga
Fucus vesiculosus L. by anti-oxidant activity and inhibition
of selected cytochrome P450 enzymes. Phytochemistry. 71:221–229.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Řezanka T, Vyhnálek O and Podojil M:
Separation and identification of lipids and fatty acids of the
marine alga Fucus vesiculosus by TLC and GC-MS. Folia
Microbiologica. 33:309–313. 1988. View Article : Google Scholar
|
|
22
|
Morris CA, Nicolaus B, Sampson V, Harwood
JL and Kille P: Identification and characterization of a
recombinant metallothionein protein from a marine alga Fucus
vesiculosus. Biochem J. 338:553–560. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin F, Giuliano AE and Van Herle AJ:
Growth inhibitory effects of flavonoids in human thyroid cancer
cell lines. Thyroid. 9:369–376. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cragg GM, Newman DJ and Yang SS: Natural
product extracts of plant and marine origin having antileukemia
potential. The NCI experience. J Nat Prod. 69:488–498. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Connor L, Huang DC, O'Reilly LA and
Strasser A: Apoptosis and cell division. Curr Opin Cell Biol.
12:257–263. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Riedl SJ and Shi Y: Molecular mechanisms
of caspase regulation during apoptosis. Nat Rev Mol Cell Biol.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krishnakumar R and Kraus WL: The PARP side
of the nucleus: Molecular actions, physiological outcomes, and
clinical targets. Mol Cell. 39:8–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
